News

 

News

2014

Axcess V Patents Granted in Australia, South Africa and Singapore Providing Patent Protection Out Through 2029

Axcess II Patent Granted in Canada

2013

Axcess IV Patent Granted in Europe

Diabetology Enters into an Academic Collaboration with Tianjin International Joint Academy of Biomedicine to Assist with the Development of Capsulin for the Chinese Market

Axcess IV Patents Granted in Japan and China

2012

Axcess III Patent Granted in US

Diabetology Limited and USV Limited, a Leading Indian Pharmaceutical Company, Announce an Exclusive License Agreement to Develop and Commercialise Oral insuln for the Indian Market

Axcess II and Axcess III Patents Granted in Japan

Axcess IV Patents Granted in Russia and Australia

Axcess II and Axcess III Patents Granted in Korea

Axcess III Patent Granted in Europe

2011

Diabetology Limited Recipient of London Stock Exchange techMARK Awards "Emerging Star Award" Nomination

Frost & Sullivan Awards Diabetology Limited
Entrepreneurial Company of the Year Award 2011
in Diabetes Therapeutics

2010

Axcess II and Axcess III Patents Granted in Australia

Axcess II Patent Granted in US

Phase II Study Results for Capsulin Published in Respected Diabetes Journal

2009

Diabetology Limited presents at the European Venture Summit 2009

Axcess II and Axcess III Patents Granted in New Zealand

Axcess III Granted in China

Diabetology Limited Nominated as One of 15 Most Innovative Healthcare Businesses by the HiT World Innovation Summit 2009

Axcess II and Axcess III Granted in India

2008

Axcess II Patent Granted in Russia

Repeat Dosing Data for Capsulin Phase II in Type 2 Diabetes Presented at the EASD Conference in Rome

Oral GLP-1 Study Presented at the EASD Conference in Rome

Axcess II and Axcess III Patents Granted in Singapore and South Africa

2007

Capsulin Goes on Display in the Science Museum, London UK

Positive Reaction to Diabetes Pill Breakthrough at ADA Conference in Chicago

Pre-2007

Phase IIa in Type 1 Diabetes Positive

New Hope for Diabetes Sufferers with Insulin Pills

Successful Phase I Study in Healthy Volunteers